Harmony Biosciences (HRMY) Acquires Epygenix Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James
April 30, 2024 12:17 PM EDTRaymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $37.00 (from $34.00) while maintaining a Outperform rating.
The analyst comments "Wakix 1Q sales of $154.6M (-8.2% q/q) slightly beat our $152.9M estimate (vs consensus $154.7M), and FY24 revenue guidance of... More
